The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

Table 4 BRAF mutation and KRAS mutation rates according to CIMP and MSI status

	Present study		Lee et al. [27]		Weisenberger et al. [20]		Ogino et al. [37]		Kambara et al. [36]
	BRAF (%)	KRAS (%)	BRAF (%)	KRAS (%)	BRAF (%)	KRAS (%)	BRAF (%)	KRAS (%)	BRAF (%)	KRAS (%)
CIMP-low/negative	0.9	34.1	1.1	31.5	1.3	35.4	6.2	41.6	10.3	37.2
CIMP-high	26.5	35.3	11.9	38.1	72.7	9.7	61.2	7.5	76.9	15.4
MSI-low/MSS	2.6	35.7	3.4				8.9	41.3	8.6	44.4
MSI-high	12.2	28.6	10.5				48.6	10.0	76.1	2.2

CIMP CpG island methylator phenotype, MSI microsatellite instability, MSS microsatellite stable

ISSN: 1471-2407